HDAC inhibition as a therapeutic strategy in myocardial ischemia/reperfusion injury

Min Xie, Yida Tang, Joseph A Hill

Research output: Contribution to journalReview article

Abstract

Reperfusion injury during myocardial infarction accounts for approximately half of final infarct size. Whereas this has been known for decades, efficacious therapy targeting reperfusion injury remains elusive. Many proteins are subject to reversible acetylation, and drugs targeting enzymes that govern these events have emerged in oncology. Among these, small molecules targeting protein deacetylating enzymes, so-called histone deacetylases (HDACs), are approved for human use in rare cancers. Now, work emerging from multiple laboratories, and in both mice and large animals, has documented that HDAC inhibition using compounds approved for clinical use confers robust cardioprotection when delivered at the time of myocardial reperfusion. Here, we summarize the key underpinnings of this science, discuss potential mechanisms, and provide a framework for a first-in-human clinical trial.

Original languageEnglish (US)
Pages (from-to)188-192
Number of pages5
JournalJournal of Molecular and Cellular Cardiology
Volume129
DOIs
StatePublished - Apr 1 2019

Fingerprint

Myocardial Reperfusion Injury
Histone Deacetylases
Reperfusion Injury
Myocardial Ischemia
Myocardial Reperfusion
Protein Transport
Enzymes
Drug Delivery Systems
Acetylation
Myocardial Infarction
Clinical Trials
Therapeutics
Neoplasms
Proteins

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

HDAC inhibition as a therapeutic strategy in myocardial ischemia/reperfusion injury. / Xie, Min; Tang, Yida; Hill, Joseph A.

In: Journal of Molecular and Cellular Cardiology, Vol. 129, 01.04.2019, p. 188-192.

Research output: Contribution to journalReview article

@article{8f9de7e7d0074cbaaf8a68d417b802f8,
title = "HDAC inhibition as a therapeutic strategy in myocardial ischemia/reperfusion injury",
abstract = "Reperfusion injury during myocardial infarction accounts for approximately half of final infarct size. Whereas this has been known for decades, efficacious therapy targeting reperfusion injury remains elusive. Many proteins are subject to reversible acetylation, and drugs targeting enzymes that govern these events have emerged in oncology. Among these, small molecules targeting protein deacetylating enzymes, so-called histone deacetylases (HDACs), are approved for human use in rare cancers. Now, work emerging from multiple laboratories, and in both mice and large animals, has documented that HDAC inhibition using compounds approved for clinical use confers robust cardioprotection when delivered at the time of myocardial reperfusion. Here, we summarize the key underpinnings of this science, discuss potential mechanisms, and provide a framework for a first-in-human clinical trial.",
author = "Min Xie and Yida Tang and Hill, {Joseph A}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.yjmcc.2019.02.013",
language = "English (US)",
volume = "129",
pages = "188--192",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - HDAC inhibition as a therapeutic strategy in myocardial ischemia/reperfusion injury

AU - Xie, Min

AU - Tang, Yida

AU - Hill, Joseph A

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Reperfusion injury during myocardial infarction accounts for approximately half of final infarct size. Whereas this has been known for decades, efficacious therapy targeting reperfusion injury remains elusive. Many proteins are subject to reversible acetylation, and drugs targeting enzymes that govern these events have emerged in oncology. Among these, small molecules targeting protein deacetylating enzymes, so-called histone deacetylases (HDACs), are approved for human use in rare cancers. Now, work emerging from multiple laboratories, and in both mice and large animals, has documented that HDAC inhibition using compounds approved for clinical use confers robust cardioprotection when delivered at the time of myocardial reperfusion. Here, we summarize the key underpinnings of this science, discuss potential mechanisms, and provide a framework for a first-in-human clinical trial.

AB - Reperfusion injury during myocardial infarction accounts for approximately half of final infarct size. Whereas this has been known for decades, efficacious therapy targeting reperfusion injury remains elusive. Many proteins are subject to reversible acetylation, and drugs targeting enzymes that govern these events have emerged in oncology. Among these, small molecules targeting protein deacetylating enzymes, so-called histone deacetylases (HDACs), are approved for human use in rare cancers. Now, work emerging from multiple laboratories, and in both mice and large animals, has documented that HDAC inhibition using compounds approved for clinical use confers robust cardioprotection when delivered at the time of myocardial reperfusion. Here, we summarize the key underpinnings of this science, discuss potential mechanisms, and provide a framework for a first-in-human clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=85062405852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062405852&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2019.02.013

DO - 10.1016/j.yjmcc.2019.02.013

M3 - Review article

C2 - 30825484

AN - SCOPUS:85062405852

VL - 129

SP - 188

EP - 192

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

ER -